Incidence, Morbidity, and Costs of Human Metapneumovirus Infection in Hospitalized Children
Background Human metapneumovirus (HMPV) causes acute respiratory tract infections in infants and children. We sought to measure the clinical and economic burden of HMPV infection in hospitalized children. Methods We conducted a retrospective cohort study from 2007 to 2013 at Primary Children's...
Saved in:
Published in | Journal of the Pediatric Infectious Diseases Society Vol. 5; no. 3; pp. 303 - 311 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.09.2016
|
Series | Editor's choice |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Human metapneumovirus (HMPV) causes acute respiratory tract infections in infants and children. We sought to measure the clinical and economic burden of HMPV infection in hospitalized children.
Methods
We conducted a retrospective cohort study from 2007 to 2013 at Primary Children's Hospital in Salt Lake City, Utah. Children <18 years of age with laboratory-confirmed HMPV infection were included. Demographic, clinical, and financial data were abstracted from the electronic medical record.
Results
During the study period, 815 children were hospitalized with laboratory-confirmed HMPV infection: 16% <6 months, 50% 6–23 months, 23% 2–4 years, and 11% 5–17 years of age. A complex chronic condition was identified in 453 (56%) children hospitalized with HMPV infection; this proportion increased with increasing age (P < .001). There was marked variation in annual HMPV hospitalization rates, ranging from 9 of 100 000 person-years in 2012–2013 to 79 of 100 000 in 2009–2010. Hospitalization rates were highest among children <2 years (200 of 100 000 person-years) and lowest among children 5–17 years of age (5 of 100 000). Of hospitalized children, 18% were treated in the intensive care unit and 6% required mechanical ventilation. The median length of stay was 2.8 days (interquartile range [IQR], 1.8–4.6) and did not vary by age. The median total hospital cost per patient was $5513 (IQR, $3850–$9946) with significantly higher costs for patients with chronic medical conditions (P < .001).
Conclusions
Human metapneumovirus infection results in a large number of hospitalizations with substantial morbidity, resource utilization, and costs. The development of a safe and effective vaccine could reduce the clinical and economic burden of HMPV. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2048-7193 2048-7207 |
DOI: | 10.1093/jpids/piv027 |